According to receptor subtypes, the patients were classified into HR (hormone receptor)+HER2-, HER2+ and TNBC (triple negative breast cancer) subtypes, and we found that PIV was significantly elevated in IBC cases in all pathological types (Figure 2C). This evidence concerns the gene NR4A1 and inflammatory breast carcinoma.